en
Font:
Аа Аа Аа
Color::
Аа Аа Аа
B/W images:
B/W - B/W +
Normal version
Substance (API)

Bafazol

Bafazol (Fabomotizole) is a selective non-benzodiazepine anxiolytic. Acting on σ1-receptors in the nerve cells of the brain, Fabomotizole stabilizes GABA/benzodiazepine receptors and restores their sensitivity to endogenous inhibitory mediators. It also enhances the bioenergetic potential of neurons and provides a neuroprotective effect, restoring and protecting nerve cells. The action of Fabomotizole is primarily realized through a combination of anxiolytic (anti-anxiety) and mild stimulating effects. Fabomotizole reduces or eliminates feelings of anxiety (worry, bad forebodings), irritability, tension (fearfulness, tearfulness, restlessness, insomnia, fear), depressive mood, somatic manifestations of anxiety (muscular, sensory, cardiovascular, respiratory, gastrointestinal symptoms), autonomic disorders (dry mouth, excessive sweating, dizziness), and cognitive disturbances (decreased concentration, memory impairment), including those that occur during stress-related disorders.

Characteristics

Trade name: Bafazol

INN: Fabomotizole

Chemical name: 5-ethoxy-2-[2-(morpholin-4-yl-ethyl)thio]-1H-benzimidazole dihydrochloride

Dosage form: powder (substance)

Field of application: manufacturing of non-sterile dosage forms

Description: white or off-white crystalline powder, hygroscopic

Registration number: UA/18760/01/01

Date of registration valid until: 02.06.2021 / 02.06.2026

Shelf life: 5 years